NCT04220658

Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers

The NAD+ Baseline Study: a Biomarker-based Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers

• Status: Suspended
• Phase: —
• Study type: Observational
• Enrollment: 170 (estimated)
• Sponsor: Elysium Health · Industry
• Sex: All
• Age: 25 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This is a single center, prospective study to evaluate correlations between epigenetic aging (as measured via DNA methylation) and NAD+ levels in healthy volunteers.

Detailed description

This biomarker study consists of a single outpatient visit to the research unit. At this visit, eligibility will be assessed and biomarker samples (blood, saliva and urine) will be collected from subjects meeting eligibility criteria. Consenting subjects with clinically significant screening lab values may be excluded from the study after biomarker sample collection (i.e., clinical lab test results will become available after the biomarker sample collection). The prescribing of drugs to humans will not be part of this protocol.

Conditions

• Epigenetics

Interventions

Type	Name	Description
OTHER	Biomarker study	Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation

Timeline

• Start date: 2019-12-19
• Primary completion: 2023-12-01
• Completion: 2023-12-03
• First posted: 2020-01-07
• Last updated: 2023-02-15

Locations

1 site across 1 country: United States